Liposomal, nanoparticle, and conjugated formulations of anticancer agents.
about
Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticlesNanotechnology and cancer.Targeted drug delivery in pancreatic cancerApproaches for optimal drug development and clinical trial design for breast cancer brain metastasis.Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy.Passive tumor targeting of renal-clearable luminescent gold nanoparticles: long tumor retention and fast normal tissue clearance.Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents.Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.Cancer cell invasion: treatment and monitoring opportunities in nanomedicine.Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.Novel anticancer polymeric conjugates of activated nucleoside analogues.Mannosylated liposomes for targeted gene delivery.Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT).The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignanciesMechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patientsOdyssey of a cancer nanoparticle: from injection site to site of action.Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.Novel anticancer nanogel conjugates of activated nucleoside analogs.Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer.L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer.Long-term silencing of intersectin-1s in mouse lungs by repeated delivery of a specific siRNA via cationic liposomes. Evaluation of knockdown effects by electron microscopy.Nanolipodendrosome-loaded glatiramer acetate and myogenic differentiation 1 as augmentation therapeutic strategy approaches in muscular dystrophyIntratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations.Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology.In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticlesMetabolism and excretion of novel pulmonary-targeting docetaxel liposome in rabbits.Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.Mifamurtide for the treatment of nonmetastatic osteosarcomaNanomaterials: applications in cancer imaging and therapy.Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept.Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.Targeted liposomal drug delivery systems for the treatment of B cell malignancies.Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.Noninvasive photothermal cancer therapy nanoplatforms via integrating nanomaterials and functional polymers.
P2860
Q28084443-427FD27F-8CBD-4248-A907-121D45EE10D6Q30452478-9210AF44-A51D-476F-BB26-88FEE88E98DEQ33625651-65473534-AE3D-40EA-9258-A364C804FA67Q33891408-311D7EC5-08A0-429D-AB17-548BEE620F09Q33901933-6387E85E-A538-4707-8A16-F4A8B22A298AQ34023045-092C5EA2-C3F4-4C73-A762-331B3AF1682FQ34265621-1CF3DD02-BF8C-4DD3-960C-A9A8C926B50CQ34538416-A97A8CF0-25BD-4815-BF3B-113FA5FC13FDQ34588395-3734CF55-8492-4F27-95C5-508B6A115029Q34708283-B3154E6F-CD37-47E3-8691-4FA7E207EC96Q35093966-F96EE347-E789-40E0-8694-0E7507257EE3Q35100986-3A856CA3-2A71-4C9D-B1BC-35B73CC1F661Q35436170-878B1635-57C5-49DA-9897-21B9DA711FDFQ35787498-375ED096-1819-4233-B667-F1B8333AD40CQ36071814-E20CD533-23B2-4D19-8734-6D0B98FE39E1Q36126057-F481BCC3-17A8-438B-B656-760F54E1375DQ36190895-65691AF1-0B68-45F3-9B0A-36DE44E52EEDQ36344679-2D4842C6-FFAE-4BA2-979D-1EAE320BB1BBQ36459196-9A583104-03AB-4D8A-9E5D-521E9F554844Q36512499-289568C9-B8A6-4093-BDDB-3710DD3EE264Q36629939-7BC182CE-3ACA-4256-A9E1-78F4A0BCA3E7Q36767246-52B6F77E-09B6-415F-A4C0-7CA2BF3DF8DDQ36774169-5A675CEE-A42F-4312-A7E8-2596A8149401Q36853886-2B843281-B977-4A8C-8733-F89718B06DCEQ36867763-C7D6D262-9B6E-42E6-9B2E-2B7A3DDF6BCFQ37057420-22B65DEB-EE37-45F5-9822-EC7F74D39582Q37095736-6E4A150F-1ADF-4DB8-BEF7-1BFC4F2BBDFEQ37213277-4CA094CE-7185-4574-886A-AB4A44AA4BF5Q37331793-DB7AE7B7-B1ED-4EA3-8310-8B23F05F15F4Q37381483-7825DB8D-6699-401C-B740-EFDC7B588C99Q37559578-51DC01B5-4B3B-409F-BD50-23D94FF90CDDQ37561973-F68C5E1D-E740-4C8C-B9BD-901ADC4C4F8DQ37827876-02527F54-A4EF-467F-BB42-17E94B943590Q37857064-9A615055-97B3-4FE9-9B25-F163A23A0E4CQ37983912-EFBA7AA5-E937-4DFE-B036-A4DD661E7B2FQ37999793-354E211B-B040-453D-B1AB-71A7EDC1072FQ38074442-D6508A3A-BC0E-4778-8F70-2F90B1CCC226Q38179032-98CC00A2-00B0-4B6A-AA7D-2F1C34EE4622Q38546964-F3EF64C2-E7E1-4093-A51C-A051217F080FQ38781032-669CBE52-D6C2-46C1-AD39-B5FC52258CE7
P2860
Liposomal, nanoparticle, and conjugated formulations of anticancer agents.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Liposomal, nanoparticle, and conjugated formulations of anticancer agents.
@ast
Liposomal, nanoparticle, and conjugated formulations of anticancer agents.
@en
type
label
Liposomal, nanoparticle, and conjugated formulations of anticancer agents.
@ast
Liposomal, nanoparticle, and conjugated formulations of anticancer agents.
@en
prefLabel
Liposomal, nanoparticle, and conjugated formulations of anticancer agents.
@ast
Liposomal, nanoparticle, and conjugated formulations of anticancer agents.
@en
P1476
Liposomal, nanoparticle, and conjugated formulations of anticancer agents.
@en
P2093
William C Zamboni
P304
P356
10.1158/1078-0432.CCR-05-1895
P407
P577
2005-12-01T00:00:00Z